alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
February 2, 2015 

Nia Daniels, ARM-108 

Federal Aviation Administration 

Office of Rulemaking, Airmen & Airspace Rules Division 

800 Independence Avenue, SW 

Washington, DC 20591 

Dear Nia Daniels: 

This letter provides the information missing from our petition (Docket No. FAA-2014-0872). The 

answers are provided in red. 

• List the maximum aircraft speed proposed for this operation, please include the airspeed 

type- 25 to 55 miles per hour 

• Provide information regarding the radio frequency spectrum - 2.6 GHz 

• Provide information regarding the proposed system for navigational guidance - GPS 

• Provide information regarding the proposed Loss Link Procedures - The aircraft will return 

to the takeoff point (home point) and execute the automatic landing procedures 

• Provide information regarding the proposed Flight Termination System (FTS)- If a loss of 

GPS or engine out situation occurs the aircraft will execute automatic landing procedures at 

its current location by flying a circular flight pattern to the ground. 

• Describe the process used to determine if the UAS is airworthy and in safe condition for 

operation in the NAS - The User Manual provides checklists for weather (including wind 

speed), pre-flight general inspections, full airframe and sensor inspections, and the preflight 

checks that are conducted automatically by the vehicle. 

• Please provide a copy of the eBee User Manual - Uploaded to docket 

The User Manual is proprietary to the manufacturer and has been uploaded and password 

protected on our docket at the www.regulations.gov website. The password has been emailed 

to the email address directed. If you have any questions, please feel free to contact me at (937) 

620-5359. 

Sincerely, 

Mr. Bret Givens 

3D Aerial Solutions, LLC 

4725 Constitutional Court 

Dayton, OH 45440
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         Eunice Kennedy Shriver National Institute of Child Health and Human Development Special Emphasis Panel; Loan Repayment Program.                    

*Date:*                         March 22, 2024.                    

*Time:*                         7:00 a.m. to 9:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6710B Rockledge Drive, Bethesda, MD 20817 (Virtual Meeting).                    

*Contact Person:*                         Christiane Robbins, Ph.D., Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS, 6710B Rockledge Drive, Rm. 2121B, Bethesda, MD 20817, (301) 451-4989,                         *crobbins@mail.nih.gov*.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: January 22, 2024.

Lauren A. Fleck,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024-01424 Filed 1-24-24; 8:45 am]

BILLING CODE 4140-01-P
August 7, 2014 

Wendy Cleland-Hamnett

Director

Office of Pollution Prevention and Toxics

U.S. Environmental Protection Agency

1200 Pennsylvania Avenue, N.W.

Washington, DC 20460

Dear Director:

This letter serves to provide the answers to the two proposed questions contained in your 

letter dated 7/23/2014. This letter contains confidential business information (CBI). This 

confidential information is shown in bracketed sections and is underlined. 

Moreover, if the EPA requires more time to complete the review process, we request an 

extension of an additional 30 days for the EPA to be able to complete their evaluation of 

NFC’s requested waiver.

Question #1 Restated: Specifically addressing NFC’s anticipated revenue from the 

contemplated import of Chloranil, and the particular timing provisions under 40 CFR 766.35 

for submitting letters of intent, test protocols, and test results after import has commenced, 

why does NFC believe that the cost of testing would be economically prohibitive (i.e., would 

effectively preclude the contemplated imports)?

Answer to Question #1: [

]
Chloranil 

August 7, 2014

Page 2 of 3

Question #2 Restated: Can NFC provide information regarding the starting materials, process 

conditions, and reaction conditions used by Jiangyn Yuhua Chemical Co., Ltd., and 

Xiangshulxian Yuanda Chemical Co., Ltd., and more specifically, how these materials and 

conditions compare to Clariant Chemical Ltd.’s manufacturer in India?

Answer to Question #2: [

]

[

]

In addition, NFC would like to discuss the MOU. By being a signatory to this document, NFC 

feels that it should be able to import Chloranil under the guidelines contained in the MOU and 

not to have to conduct the D/F Test Rule Testing.
Chloranil 

August 7, 2014

Page 3 of 3

If you have any questions or concerns regarding this information, please contact me at your 

earliest convenience.

Sincerely, 

Phillip McCarter

 Vice President

cc: Jay Dickson, Nation Ford Chemical

 John Dickson, Nation Ford Chemical

 Steve Schmidt, Sun Chemical

 Hiroshi Dodohara, US EPA
Order entered August 19, 2014

In The 

## Court of Appeals **Fifth District of Texas at Dallas**

No. 05

- 14

- 00430

- CV

REHEMA OLUFEMI

- JONES AND ALL OTHER OCCUPANTS, Appellant s

V.

VAN LE AND MAI NGO, Appellee s
On Appeal from the County Court at Law No. 2 Dalla s County, Texas Trial Court Cause No. CC

- 13

- 06801

- B



### O RDER
In an order dated August 13, 2014, we granted appellants’ motion for an extension of time to file the reporter’s record and a brief to the extent that we instructed appellants to file proof of pay ment for the reporter’s record within five days. Before the Court is the August 18, 2014 motion of Lanetta Williams, Official Court Reporter for County Court at Law No. 2 of Dallas County, Texas, requesting an extension of time to file the reporter’s reco rd. In her motion, Lanetta Williams informs the Court that appellants have paid for the record. Accordingly, we GRANT the motion. The reporter’s record shall be filed on or before SEPTEMBER 18, 2014 . Appellants’ brief will be due thirty days after the reporter’s record is
filed. See T EX

. R. A PP

. P. 38.6(a)(2).

/s/ CAROLYN WRIGHT CHIEF JUSTICE
CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of LitFunding Corp. (the "Company") on
Form 10-Q for the period ended September 30, 2003, as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Morton Reed,
President and Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:

     (1) The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

     (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.


                                  /s/ Morton Reed
                                  --------------------------------------
                                  Morton Reed
                                  President and Chief Executive Officer
Dated: December 12, 2003




<PAGE>



                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of LitFunding Corp. (the "Company") on
Form 10-Q for the period ended September 30, 2003, as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, David Cohen, Chief
Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

     (1) The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

     (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.


                                  /s/ David Cohen
                                  --------------------------------------
                                  David Cohen
                                  Chief Financial Officer
Dated: December 12, 2003
#### Richard Douglas CASAVAN, Petitioner—Appellant, v. Joan PALMATEER, Respondent—Appellee.

No. 01-36052.

D.C. No. CV-00-06152-HJF.

United States Court of Appeals, Ninth Circuit.

Argued and Submitted Dec. 6, 2002.

Decided Jan. 27, 2003.

Before B. FLETCHER, KLEINFELD and McKEOWN, Circuit Judges.

MEMORANDUM *

As the district court correctly held, Ca-savaris claim that he was denied due process when his sentence was amended is procedurally barred. Although both the Oregon Court of Appeals and Supreme Court denied his state petition without opinion, in its relevant briefing the State did not argue the merits, but only asserted state procedural bars to Casavaris claim. Because the State briefed procedural issues but not the merits, we may infer the state court decided the case for the State on the state procedural issues in its summary affirmance.1 Because Casavaris claim is procedurally defaulted, we need not reach the merits.

AFFIRMED.

*

 This disposition is not appropriate for publication and may not be cited to or by the courts of this circuit except as provided by Ninth Circuit Rule 36-3.

1

. *See Coleman v. Thompson,*501 U.S. 722, 740, 111 S.Ct. 2546, 115 L.Ed.2d 640 (1991) (holding that state court summary dismissal of appeal "fairly appears” to have relied on state procedural ground when government’s sole ground for motion to dismiss was that appeal was untimely); *Siripongs v. Calderon,*35 F.3d 1308, 1317 (9th Cir.1994) (describing state court opinion in *Coleman:*"the state had rested its argument solely upon a single procedural bar and the state court had obviously accepted its argument.”).
II

Calendar No. 267

104TH CONGRESS

1ST SESSION S. 1465

To extend au pair programs.

IN THE SENATE OF THE UNITED STATES

DECEMBER 11, 1995

Mr. HELMS (for himself, Mr. DODD, and Mr. KERRY) introduced the following

bill; which was read twice and referred to the Committee on Foreign Relations

DECEMBER 12, 1995

Reported by Mr. HELMS without amendment

A BILL

To extend au pair programs.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. EXTENSION OF AU PAIR PROGRAMS.

4 (a) REPEAL.—Section 8 of the Eisenhower Exchange

5 Fellowship Act of 1990 (Public Law 101–454) is repealed.

6 (b) AUTHORITY FOR AU PAIR PROGRAMS.—The Di7 rector of the United States Information Agency is author8 ized to continue to administer an au pair program, operat9 ing on a world-wide basis, through fiscal year 1999.
2

•S 1465 RS

1 (c) REPORT.—Not later than October 1, 1998, the

2 Director of the United States Information Agency shall

3 submit a report regarding the continued extension of au

4 pair programs to the Committee on Foreign Relations of

5 the Senate and the Committee on International Relations

6 of the House of Representatives. This report shall specifi7 cally detail the compliance of all au pair organizations

8 with regulations governing au pair programs as published

9 on February 15, 1995.

Calendar No. 267

104TH CONGRESS

1ST SESSION S. 1465

A BILL

To extend au pair programs.

DECEMBER 12, 1995

Reported without amendment
II

104TH CONGRESS

2D SESSION S. 1654

To apply equal standards to certain foreign made and domestically produced

handguns.

IN THE SENATE OF THE UNITED STATES

MARCH 28, 1996

Mrs. BOXER (for herself and Mr. BRADLEY) introduced the following bill;

which was read twice and referred to the Committee on the Judiciary

A BILL

To apply equal standards to certain foreign made and

domestically produced handguns.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the ‘‘Junk Gun Violence

5 Protection Act’’.

6 SEC. 2. FINDINGS.

7 The Congress finds that—

8 (1) the prohibition on the importation of hand9 guns that are not generally recognized as particu10 larly suitable for or readily adaptable to sporting
2

•S 1654 IS

1 purposes, often described as junk guns or Saturday

2 night specials, has led to the creation of a high-vol3 ume market for these weapons that are domestically

4 manufactured;

5 (2) traffic in junk guns constitutes a serious

6 threat to public welfare and to law enforcement offi7 cers, and the use of such firearms is increasing;

8 (3) junk guns are used disproportionately in the

9 commission of crimes;

10 (4) of the firearms traced in 1995, the 3 fire11 arms most commonly traced to crimes were junk

12 guns; and

13 (5) the domestic manufacture, transfer, and

14 possession of junk guns should be restricted.

15 SEC. 3. RESTRICTION ON MANUFACTURE, TRANSFER, AND

16 POSSESSION OF CERTAIN HANDGUNS.

17 (a) RESTRICTION.—Section 922 of title 18, United

18 States Code, is amended by adding at the end the follow19 ing new subsection:

20 ‘‘(y)(1) It shall be unlawful for a person to manufac21 ture, transfer, or possess a junk gun that has been shipped

22 or transported in interstate or foreign commerce.

23 ‘‘(2) Paragraph (1) shall not apply to—

24 ‘‘(A) the possession or transfer of any junk gun

25 otherwise lawfully possessed under Federal law on
3

•S 1654 IS

1 the date of the enactment of the Junk Gun Violence

2 Protection Act;

3 ‘‘(B) any firearm or replica of a firearm that

4 has been rendered permanently inoperative;

5 ‘‘(C) the manufacture for, transfer to, or pos6 session by the United States or a State or a depart7 ment or agency of the United States, or a State or

8 a department, agency, or political subdivision of a

9 State, or a transfer to or possession by a law en10 forcement officer employed by such an entity for law

11 enforcement purposes (whether on or off duty); or

12 ‘‘(D) the manufacture, transfer, or possession

13 of a junk gun by a licensed manufacturer or licensed

14 importer for the purposes of testing or experimen15 tation authorized by the Secretary.’’.

16 (b) DEFINITION OF JUNK GUN.—Section 921(a) of

17 title 18, United States Code, is amended by adding at the

18 end the following new paragraph:

19 ‘‘(33)(A) The term ‘junk gun’ means any firearm

20 that is not described in section 925(d)(3), and any regula21 tions issued under such section.’’.

Æ
<PAGE>   1
                                                                      EXHIBIT 21



                           SUBSIDIARIES OF REGISTRANT*

<TABLE>
<CAPTION>
                          Name                                          State of Incorporation
                          ----                                          ----------------------
<S>                                                                          <C>
Subsidiaries Incorporated in the United States:
-----------------------------------------------

  C/P Products Corp.  . . . . . . . . . . . . . . . . . .                      Indiana

  United Sales & Warehouse of Texas, Inc. . . . . . . . .                      Texas

Foreign Subsidiaries:
---------------------

  The Coast Distribution System (Canada) Inc. . . . . . .                      Quebec, Canada
</TABLE>

-------------------
*   In accordance with the descriptions set forth in Paragraph (b) of Item 601
    of Regulation S-K, there have been omitted those subsidiaries that, if
    considered in the aggregate as a single subsidiary, would not constitute a
    significant subsidiary as of December 31, 1995.
#### UNITED STATES of America, Plaintiff-Appellee, v. William SHORTER, Jr., Defendant-Appellant.

No. 02-7783.

United States Court of Appeals, Fourth Circuit.

Submitted Jan. 30, 2003.

Decided Feb. 5, 2003.

William Shorter, Jr., Appellant Pro Se. Morris Rudolph Parker, Jr., Assistant United States Attorney, Alexandria, Virginia, for Appellee.

Before WIDENER, NIEMEYER, and TRAXLER, Circuit Judges.

Dismissed by unpublished PER CURIAM opinion.

PER CURIAM.

William Shorter, Jr., filed an appeal on July 17, 2002, in a district court case in which he challenges his sentence. The notice of appeal does not identify an order from which he appeals. We have examined the notice of appeal and the record in the district court action and find no underlying order to review. We therefore dismiss the appeal. We deny all Shorter’s pending motions. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

*DISMISSED.*
Exhibit 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of In Veritas Medical Diagnostics,  Inc.
(the  "Company")  on Form 10-QSB for the quarter ended October 31, 2005 as filed
with the Securities and Exchange  Commission on the date hereof (the  "Report"),
I, John Fuller, Chief Executive Officer of the Company,  certify, pursuant to 18
U.S.C. section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities and Exchange Act of 1934; and

(2) The  information  contained in the Report fairly  presents,  in all material
respects, the financial condition and result of operations of the Company.

A signed  original of this  written  statement  required by Section 906 has been
provided  to In Veritas  Medical  Diagnostics,  Inc.  and will be retained by In
Veritas Medical  Diagnostics,  Inc. and furnished to the Securities and Exchange
Commission or its staff upon request.



December 20, 2005                          /s/ John Fuller
                                           ---------------
                                           John Fuller
                                           President and Chief Executive Officer
Exhibit 23.1
   (1)
    
    Registration Statement (Form S-3 No. 333-143825) of Onyx Pharmaceuticals, Inc.,(2)
    
    Registration Statement (Form S-3 No. 333-134565) of Onyx Pharmaceuticals, Inc.,(3)
    
    Registration Statement (Form S-3 No. 333-33322) of Onyx Pharmaceuticals, Inc.,(4)
    
    Registration Statement (Form S-8 No. 333-150928) pertaining to the 2005 Equity
Incentive Plan of Onyx Pharmaceuticals, Inc.,(5)
    
    Registration Statement (Form S-8 No. 333-143309) pertaining to the 2005 Equity
Incentive Plan and the 1996 Employee Stock Purchase Plan of Onyx
Pharmaceuticals, Inc.,(6)
    
    Registration Statement (Form S-8 No. 333-134567) pertaining to the 1996
Employee Stock Purchase Plan of Onyx Pharmaceuticals, Inc.,(7)
    
    Registration Statement (Form S-8 No. 333-126089) pertaining to the 2005 Equity
Incentive Plan, 1996 Equity Incentive Plan, and the 1996 Non-Employee
Directors Stock Option Plan of Onyx Pharmaceuticals, Inc.,(8)
    
    Registration Statement (Form S-8 No. 333-120324) pertaining to the 1996 Equity
Incentive Plan of Onyx Pharmaceuticals, Inc.,(9)
    
    Registration Statement (Form S-8 No. 333-110469) pertaining to the 1996 Equity
Incentive Plan and the 1996 Non-Employee Directors Plan of Onyx
Pharmaceuticals, Inc.,(10)
    
    Registration Statement (Form S-8 No. 333-96895) pertaining to the 1996 Equity
Incentive Plan and the 1996 Employee Stock Purchase Plan of Onyx
Pharmaceuticals, Inc.,(11)
    
    Registration Statement (Form S-8 No. 333-64706) pertaining to the 1996 Equity
Incentive Plan and the 1996 Non-Employee Directors Stock Option Plan of Onyx
Pharmaceuticals, Inc.,(12)
    
    Registration Statement (Form S-8 No. 333-48146) pertaining to the 1996 Equity
Incentive Plan, the 1996 Non-Employee Directors Stock Option Plan and the
Employee Stock Purchase Plan of Onyx Pharmaceuticals, Inc.,(13)
    
    Registration Statement (Form S-8 No. 333-84113) pertaining to the 1996 Equity
Incentive Plan of Onyx Pharmaceuticals, Inc.,(14)
    
    Registration Statement (Form S-8 No. 333-60805) pertaining to the 1996 Equity
Incentive Plan and the 1996 Employee Stock Purchase Plan of Onyx
Pharmaceuticals, Inc.,(15)
    
    Registration Statement (Form S-8 No. 333-34681) pertaining to the 1996 Equity
Incentive Plan, as amended, of Onyx Pharmaceuticals, Inc., and(16)
    
    Registration Statement (Form S-8 No. 333-04839) pertaining to the 1996 Equity
Incentive Plan, the 1996 Employee Stock Purchase Plan, and the 1996
Non-Employee Directors Stock Option Plan of Onyx Pharmaceuticals, Inc.
Exhibit 32
 Written Statement of Chief Executive Officer and Chief Financial Officer Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002
    /s/ Gary H. HuntGary H. HuntInterim Chief Executive
OfficerMay 27, 2009 /s/  Richard W. PehlkeRichard W. PehlkeChief Financial OfficerMay 27, 2009